System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced Cost [0.03%]
高水平的生存率和较低的成本造血干细胞移植项目的系统级改革
Shernan G Holtan,Megan M Herr,Kanwal Mallhi et al.
Shernan G Holtan et al.
Background: Practice variation in allogeneic hematopoietic cell transplantation may contribute to preventable toxicity, non-relapse mortality, and excess cost. We evaluated outcomes occurring with the implementation of a ...
Peritransplant KMT2A-r Molecular MRD Dynamics and Relapse Timing Stratify Outcomes After Allo-HSCT in CR1 Acute Leukemia [0.03%]
allo-HSCTCR1急性白血病中，KMT2A-r分子MRD的动态变化及复发时间对预后的影响
Bai-Qing Sun,Yan-Li Zhao,Jian-Ping Zhang et al.
Bai-Qing Sun et al.
Harnessing the Power of Two: High-Dose Stem Cell Haploidentical Transplant in Hematologic Malignancies - A Prospective Trial [0.03%]
双重力量的利用：在血液系统恶性肿瘤中进行高剂量造血干细胞单倍型移植的一项前瞻性试验
Xia Bi,Boula Gattas,Dolores Grosso et al.
Xia Bi et al.
Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma [0.03%]
CAR-T细胞治疗后复发/难治性多发性骨髓瘤结局受疾病生物学和桥接策略的影响
Irene Strassl,Alexander Nikoloudis,Lina Zoe Ruesing et al.
Irene Strassl et al.
Background: Bridging therapy is commonly administered prior to B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myeloma (RRMM) to maintain disease co...
Real-world use of maribavir for refractory CMV infection and intolerance to conventional anti-CMV agents after allogeneic hematopoietic cell transplantation [0.03%]
异基因造血细胞移植后难治性巨细胞病毒感染及常规抗病毒药物不耐受患者使用maribavir的现实世界应用
Risa Nishiyama,Ayumu Ito,Yu Akahoshi et al.
Risa Nishiyama et al.
Background: Maribavir (MBV) is approved for refractory or resistant cytomegalovirus (CMV) infection after transplantation. However, real-world data on allogeneic hematopoietic cell transplantation (allo-HCT) recipients re...
Do We Sin When Treating Patients with Higher-Risk Myelodysplastic Syndromes? [0.03%]
高危骨髓增生异常综合征患者治疗方案的选择有罪吗？
Sangeetha Venugopal,Mikkael A Sekeres
Sangeetha Venugopal
Biju George,Uday Kulkarni
Biju George
Comparison of Carmustine-, Lomustine-, and Nitrosourea-free Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Lymphoma (auto-HTC): Results from the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR) [0.03%]
巴西造血细胞移植登记处（HCTBR）自体造血干细胞移植治疗淋巴瘤的白消安、洛莫司汀和无硝基脲类方案的对比研究结果
Abrahão Elias Hallack Neto,Vanderson Rocha,Eliana Miranda et al.
Abrahão Elias Hallack Neto et al.
None. Keywords: autologous hematopoietic cell transplantation; conditioning regimens; lomustine; lymphoma. ...
Reduced-dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in matched donor allogeneic stem cell transplantation: a systematic review of efficacy and toxicity [0.03%]
减量移植后环磷酰胺预防单倍型和_matched_供者异基因造血干细胞移植移植物抗宿主病的系统评价：有效性和毒副作用
Areez Shafqat,Malaz El-Sibai,Abdulrahman Nasiri et al.
Areez Shafqat et al.
The standard 100 mg/kg dose of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis after matched allogeneic stem cell transplantation (ASCT) is associated with important toxicities, such as infections, h...